Showing 2641-2650 of 3315 results for "".
- Atsena Therapeutics Announces 6-Month Data from Phase 1/2 Clinical Trial of ATSN-101 to be Presented at ARVOhttps://modernod.com/news/atsena-therapeutics-announces-6-month-data-from-phase-12-clinical-trial-of-atsn-101-to-be-presented-at-arvo/2481523/Atsena Therapeutics announced that 6-month safety and efficacy data from the ongoing phase 1/2 clinical trial of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1) will be presented at the Association for Research in Vision and Ophthalmol
- Abionyx Pharma Announces Its Strategy in Ophthalmologyhttps://modernod.com/news/abionyx-pharma-announces-its-strategy-in-ophthalmology/2481506/France-based Abionyx Pharma announced announced its strategy in ophthalmology and new positive preclinical results in two technological platforms: apotherapy and biovectorisation. "The acquisition of IRIS Pharma, one of the world leaders in contract research in ophthalmology,
- Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for RP and LCA Gene Therapyhttps://modernod.com/news/ocugen-announces-fda-approval-for-enrollment-of-pediatric-patients-in-ongoing-ocu400-phase-12-clinical-trial-for-rp-and-lca-gene-therapy/2481499/Ocugen announced that the FDA approved enrolling pediatric patients in the ongoing OCU400 phase 1/2 trial. OCU400 is a gene therapy candidate for retinitis pigmentosa (RP) and Leber Congenital Amaurosis (LCA). “This approval moves us one step closer in our efforts to bri
- Théa Open Innovation and Galimedix Partner to Develop and Commercialize GAL-101 for Ophthalmic Indicationshttps://modernod.com/news/thea-open-innovation-and-galimedix-partner-to-develop-and-commercialize-gal-101-for-ophthalmic-indications/2481497/Théa Open Innovation and Galimedix Therapeutics announced that they have signed a licensing agreement in which Galimedix will grant Théa exclusive rights for the development and commercialization of GAL-101, Galimedix’s lead disease-modifying compound, for the topical and
- Study: Reduced Oxygen Transport to the Retina Contributing to Damage to the Fine Blood Vessels Causes Diabetic Retinopathyhttps://modernod.com/news/study-reduced-oxygen-transport-to-the-retina-owing-to-damage-to-the-fine-blood-vessels-causes-diabetic-retinopathy/2481492/Researchers in Austria have now found evidence for a previously suspected connection: reduced oxygen transport to the retina contributes to damage to the fine blood vessels, causing diabetic retinopathy. A common complication of diabetes, this retinal damage can ultimately lead to blind
- AI-based Systems Can Help Identify Rapidly Advancing Age-Related Macular Degenerationhttps://modernod.com/news/ai-based-systems-can-help-identify-rapidly-advancing-age-related-macular-degeneration/2481490/Researchers supported by the National Eye Institute (NEI) are developing artificial intelligence/machine learning (AI/ML)-based systems that not only screen for AMD but also predict which patients will likely progress to late within 2 years,
- Visus Therapeutics Completes Enrollment in BRIO-I Phase 3 Trial of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-completes-enrollment-in-brio-i-a-phase-3-clinical-trial-of-brimochol-pf-for-the-treatment-of-presbyopia/2481483/Visus Therapeutics announced it has completed patient enrollment and the last visit had been conducted in BRIO-I, a phase 3 trial for its lead asset, Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia. “We are thrilled to have reache
- Aviceda Submits Investigational New Drug Application for AVD-104 for the Treatment of GA Associated with AMDhttps://modernod.com/news/aviceda-submits-investigational-new-drug-application-for-avd-104-for-the-treatment-of-ga-associated-with-amd/2481477/Aviceda Therapeutics announced that it has submitted an investigational new drug (IND) application to the FDA. The IND supports the use of its lead intravitreal ocular asset, AVD-104 (a novel glycan-coated nanoparticle), for the treatment of GA secondary to AMD. Aviceda previously announced
- BioCareSD and AllyRetina GPO Partner to Help Retina Providers Improve Patient Care and Increase Efficiencyhttps://modernod.com/news/biocaresd-and-allyretina-gpo-partnership-to-help-retina-providers-improve-patient-care-and-increase-efficiency/2481473/BioCareSD announced its partnership with AllyRetina. Debuting at the American Society of Retina Specialists (ASRS) 24th Annual Business of Retina conference this week, AllyRetina will serve its GPO members through its physician leadership, a seasoned management team, and innovative tools and
- Researchers Discover Therapeutic Target to Aid in Glaucoma Treatmenthttps://modernod.com/news/researchers-discover-therapeutic-target-to-aid-in-glaucoma-treatment/2481470/Indiana University School of Medicine researchers have identified a new therapeutic target that could lead to more effective treatment of glaucoma, according to an article posted on the university website.